2. Search Result
Search Result
Results for "

RNAi

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

2

Biochemical Assay Reagents

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-132604
    Fazirsiran

    ARO-AAT

    		 Small Interfering RNA (siRNA) Metabolic Disease
    Fazirsiran (ARO-AAT) is a second-generation RNAi agent. Fazirsiran consistes of a cholesterol-conjugated RNAi trigger (chol-RNAi) to selectively degrade Alpha1-antitrypsin (AAT) mRNA by RNAi and a melittin-derived peptide conjugated to N-acetylgalactosamine (NAG) formulated as the excipient EX1 to promote endosomal escape of the chol-RNAi in hepatocytes . Fazirsiran can be used in the study of Alpha-1 Antitrypsin Deficiency (AATD) liver disease.
    Fazirsiran
  • HY-132604A
    Fazirsiran sodium

    ARO-AAT sodium

    		 Small Interfering RNA (siRNA) Metabolic Disease
    Fazirsiran sodium is a second-generation RNAi agent. Fazirsiran sodium consistes of a cholesterol-conjugated RNAi trigger (chol-RNAi) to selectively degrade Alpha1-antitrypsin (AAT) mRNA by RNAi and a melittin-derived peptide conjugated to N-acetylgalactosamine (NAG) formulated as the excipient EX1 to promote endosomal escape of the chol-RNAi in hepatocytes . Fazirsiran sodium can be used in the study of Alpha-1 Antitrypsin Deficiency (AATD) liver disease.
    Fazirsiran sodium
  • HY-145411
    PEG2000-C-DMG

    		Liposome Endocrinology
    PEG2000-C-DMG, a pegylated lipid, can be used for the preparation of Onpattro. Onpattro, a hepatically directed investigational RNAi therapeutic agent, harnesses this process to reduce the production of mutant and wild-type transthyretin by targeting the 3′ untranslated region of transthyretin mRNA .
    PEG2000-C-DMG
  • HY-112523A
    DMTAP

    		Others Others
    DMTAP is a cationic lipid that can be used for delivery of DNA, RNAi and drugs .
    DMTAP
  • HY-145797
    L343

    		Liposome Others
    L343 is an ionizable cationic lipidoid and can be used to synthetic liposomes for systemic delivery of RNAi therapeutics.
    L343
  • HY-132606
    Nedosiran

    DCR-PHXC

    		 Small Interfering RNA (siRNA) Metabolic Disease
    Nedosiran (DCR-PHXC) is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH). Nedosiran represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD). Nedosiran is a GalNAc-dsRNA conjugate .
    Nedosiran
  • HY-132613
    Lumasiran sodium

    		Small Interfering RNA (siRNA) Metabolic Disease
    Lumasiran sodium, an investigational RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase. Lumasiran sodium reduces urinary oxalate excretion, the cause of progressive kidney failure in primary hyperoxaluria type 1 (PH1) .
    Lumasiran sodium
  • HY-132587
    Fitusiran

    ALN-AT3SC; SAR439774

    		 Small Interfering RNA (siRNA) Factor Xa Others
    Fitusiran (ALN-AT3SC), an small interfering RNA, specifically targets antithrombin (AT) messenger RNA to lower production of AT in the liver. Fitusiran increases thrombin generation and has the potential for the research of the hemophilia .
    Fitusiran
  • HY-150224
    GalNAc unconjugated/naked Fitusiran sodium

    		Small Interfering RNA (siRNA) Factor Xa Others
    GalNAc unconjugated/naked Fitusiran (sodium), an small interfering RNA without GalNAc conjugation, specifically targets antithrombin (AT) messenger RNA to lower production of AT in the liver. Fitusiran increases thrombin generation and has the potential for the research of the hemophilia .
    GalNAc unconjugated/naked Fitusiran sodium
  • HY-132587A
    Fitusiran sodium

    ALN-AT3SC sodium; SAR439774 sodium

    		 Factor Xa Others
    Fitusiran sodium, an small interfering RNA, specifically targets antithrombin (AT) messenger RNA to lower production of AT in the liver. Fitusiran sodium increases thrombin generation and has the potential for the research of the hemophilia .
    Fitusiran sodium
  • HY-116999
    IR415

    		HBV Infection
    IR415 is a potent anti-HBV agent and inhibits HBV replication by blocking the HBx activity. IR415 selectively interacts with HBx (Kd=2 nM) and blocks HBV-mediated RNAi suppression, reverses the inhibitory effect of HBx protein on the activity of the dicer endoribonuclease . HBx: hepatitis B virus X protein.
    IR415
  • HY-147077
    Triantennary GalNAc-1

    		Others Inflammation/Immunology
    Triantennary GalNAc-1 is a triantennary N-acetylgalactosamine (GalNAc) that can be conjugated to the 3' end of the sense strand of siRNA. GalNAc promotes targeted delivery of siRNA to liver cells both in vitro and in vivo [1].
    Triantennary GalNAc-1
  • HY-132603A
    AB-729 sodium

    		HBV Small Interfering RNA (siRNA) Infection
    AB-729 sodium is a siRNA specifically designed to inhibit viral replication and reduces HBV antigens . AB-729 conjugates to a trimer of N-acetylgalactosamine (GalNAc) ligand that promotes uptake into hepatocytes via the asialoglycoprotein receptor (ASGR).
    AB-729 sodium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: